Posted by Michael Wonder on 13 Nov 2017
NICE ‘no’ for short bowel syndrome drug Revestive
13 November 2017 - UK medicines cost-effectiveness watchdog NICE has published draft guidance today that does not recommend Revestive (teduglutide) for treatment of people with short bowel syndrome.
The drug, from Ireland-headquartered Shire, is licensed for treating patients in a stable condition after their intestine has adapted post-surgery.
The cost-effectiveness estimates for teduglutide are £193,549 ($255,872) per quality-adjusted life year gained in adults. This is much higher than what NICE normally considers an acceptable use of National Health Service resources.
